Cipla's US subsidiary secured exclusive rights to commercialize QL2107, Qilu Pharmaceutical's phase 3 biosimilar candidate to Keytruda, ahead of the reference biologic's anticipated 2028 patent expiration.
|Articles|July 24, 2017
BioPhorum Launches Biomanufacturing Technology Roadmap
Author(s)BioPharm International Editors
Industry collaboration group releases technology roadmap to address pressure on biopharmaceutical manufacturers to innovate biomanufacturing processes.
Advertisement
On July 20, 2017, the BioPhorum Operations Group (BPOG), a cross-industry collaboration, announced it published The Technology Roadmap for the Biopharmaceutical Manufacturing Industry, to address the pressure biomanufacturers face to innovate biomanufacturing platforms. Biomanufacturers are facing pressure from current biopharmaceutical industry trends, including continued market growth, the arrival of new product groups, cost pressure, and the trend toward localized manufacture. BPOG’s technology roadmap identifies common biomanufacturer needs and shares those needs with supply partners, academics, regional innovation hubs, regulators, and government agencies, to align directions and enable pre-competitive collaboration.
The technology roadmap comprises eight documents, including an executive summary, an overview, and sections on six enabling technologies and capabilities. Thirty-one member companies contributed to the roadmap, with additional input from leading academics and regional innovation hubs. In total, 160 people are actively involved in the roadmapping process, according to BPOG in a company press release. Six teams visualized future manufacturing scenarios and were tasked with roadmapping key enabling technologies and capabilities, including: in-line monitoring and real-time release; knowledge management; supply partnership management; process technology; automated facility; and modular and mobile systems.
Source:
Advertisement
Related to this article
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Aptar Pharma's Nanopharm business will lead inhaled formulation development and device assessment for ACT-101, Aceso Therapeutics' antisense oligonucleotide candidate designed to correct CFTR protein function in cystic fibrosis patients carrying the F508del mutation.
Bristol Myers Squibb's GPRC5D-Directed CAR T Cell Therapy Meets Primary Endpoint in Multiple Myeloma
Bristol Myers Squibb reported positive topline phase 2 results for arlocabtagene autoleucel, a potential first-in-class GPRC5D-directed CAR T cell therapy, in patients with quadruple-class exposed relapsed and refractory multiple myeloma who had already received a prior BCMA-targeted therapy.
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Advertisement
Advertisement